While at the American Health Law Association's 2026 Health Care Transactions Conference in Nashville, the Levin Associates team asked several attendees, including Baker Donelson Shareholder Glenn Prives, how ongoing policy uncertainty at both the state and federal levels is impacting healthcare deal strategy, valuation and timelines. Attendees noted that uncertainty around Medicaid budgets, reimbursement changes and proliferating state regulatory reviews is extending deal timelines, leading to more cautious valuations, and increasing diligence requirements.